Kymriah Manufacturing Issues Spell Trouble for Commercialization of Novartis CAR-T Therapy

Just days after announcing its partnership with French CDMO Cell for Cure, Novartis has disclosed it’s been facing some US manufacturing problems with the CAR-T cancer therapy Kymriah. While the company didn’t elaborate on the exact type of product variability, they did say that they’re working closely with the FDA to resolve the issue.